Dr. Karl Kucher joins SOLVO Strategic Advisory Board
2006-09-19
SOLVO Biotechnology announced today the appointment of Karl Kuchler to its Strategic Advisory Board. Dr. Kuchler is widely recognized in the drug transporter community as leader and champion of collaboration between academia and industry!
"We are extremely pleased and deeply honored to have such a leading scientist as Karl Kuchler join our Strategic Advisory Board" said SOLVO's President and CEO Mr Ern Duda.
Karl Kuchler, PhD is the Associate Professor of Molecular Genetics at the Medical University Vienna, Max F. Perutz Laboratories, Department of Medical Biochemistry, Austria. He was trained as a biochemist at the Technical University of Graz where he also received his PhD. His research interests are focused on the following areas: Molecular structure-function analysis and expression regulation of ABC proteins in lower eukaryotes (yeast, fungal pathogens, stress response, drug resistance mechanisms and signal transduction); Molecular mechanism of fungal virulence and host-pathogen interaction (Signal transduction during host cell invasion, immune response, animal models to study pathogenesis); Molecular medicine and systems biology of novel genes encoding mammalian ABC proteins (Genetic analysis of hepatic, intestinal and brain ABC transporters).
Dr Kuchler has over 75 peer-reviewed publications; he is the editor of a number of books and various journals and the author of 2 patents.
"Dr. Kuchler brings tremendous experience and broad scientific prospective into our Strategic Advisory Board. We are very excited and look forward to working with him for the development and promotion of new drug transporter technologies that will help reduce the cost and time of drug development" commented Dr. Peter Krajcsi, Chief Scientific Officer of SOLVO Biotechnology.
About Solvo Biotechnology
SOLVO Biotechnology - "The Transporter Company" has been the pioneer and the leader in the commercialization of Membrane Transporter technologies, including therapeutics, diagnostics and drug discovery assays. The company offers drug discovery products and services to pharmaceutical, biotechnology and consumer goods industries, relevant to many therapeutic areas and product categories. All major pharmaceutical and biotechnology companies use SOLVO's assays, either in-house, or as contracted research to significantly reduce the time and cost of the compound development process. By now, it is a common knowledge that efflux and various uptake transporters play key roles in the function of the Blood-Brain Barrier (BBB), the blood-CSF barrier, the blood-testis barrier, the intestinal epithelia (absorption), the airway epithelia, the liver epithelia and the kidney epithelia. SOLVO products can be used to study the transport properties of these pharmacological barriers. SOLVO's mainstream products are its High Throughput in vitro assay systems to detect the interaction of test compounds with a wide array of ABC Transporter proteins, and cell lines expressing various uptake transporter proteins used for in vitro ADME/Tox, oncology drug research and MDR modulating agent discovery. For additional information, please refer to the company's web site at www.solvo.com or call +36-23-503-937.
CONTACT:
Gbor Heltovics
Business Development Director
SOLVO Biotechnology
+36-23-503-937
info@solvo.com